Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Moberg Derma, a developer of patented topical pharmaceuticals for the treatment of common disorders through the use of drug delivery, has received CE mark for its Kaprolac Skin Repair & Hydration for the treatment of atopic eczema and dry skin.
Subscribe to our email newsletter
Kaprolac Skin Repair & Hydration is a steroid-free treatment for eczema, for topical use, which is designed to treat the most common discomforts such as thickened, dry, itchy and red skin.
Moberg Derma CEO Peter Wolpert said the benign safety profile makes Kaprolac product an alternative for patients who are affected by recurrent and protracted problems with eczema.
"In a comparative study, the product demonstrated an ability to reinforce the skin barrier and re-hydrate the skin than a topical pharmaceutical based on propylene glycol," Wolpert said.